Search Results - "Choudhary, Jatin"

INHIBITION OF HDAC3 DURING IMMUNE STIMULUS AMELIORATES SEX-SPECIFIC DEPRESSIVE-LIKE BEHAVIOUR AND ABERRANT MICROGLIAL MORPHOLOGY by Sullivan, Olivia, Choudhary, Jatin, Kim, Jennifer, Ciernia, Annie

Get full text

High-Grade Gastrointestinal Neuroendocrine Carcinomas: Multidisciplinary Approach Can Improve Survival Outcomes by Syed, Noorzia, Ramaswamy, Anant, Dhanawat, Aditya, Joarder, Ritam, Choudhary, Jatin, Patel, Dhwani, Bhargava, Prabhat, Bal, Munita, Yadav, Subhash, Bhandare, Manish, Chaudhari, Vikram, Shrikhande, Shailesh V., Goel, Mahesh, Patkar, Shraddha, deSouza, Ashwin, Saklani, Avanish, Kazi, Mufaddal, Puranik, Ameya, Ostwal, Vikas

“…Purpose There is limited evidence for the presentation patterns and outcomes of patients with high-grade gastrointestinal neuroendocrine carcinomas (HG-NEC)…”
Get full text

Why oncology? by Choudhary, Jatin

Get full text

Real-world data of use of nivolumab in platinum refractory head and neck cancers by Choudhary, Jatin, Kumar, Hemanth, Ravikrishna, Madala, Patil, Vijay Maruti, Prabhash, Kumar

“…e18686 Background: Nivolumab is one of the approved agents for platinum refractory and second line treatment in head and neck cancers as per NCCN guidelines…”
Get full text

Patient’s perception of cancer treatment outcomes in geriatric age groups: A retrospective analysis from a tertiary care centre in India by Choudhary, Jatin, Noronha, Vanita, Menon, Nandini Sharrel, Shah, Minit Jalan, Pillai, Anupa, Kumar, Anita, Rao, Abhijith Rajaram, Pawar, Akash, Dhekale, Ratan, Prabhash, Kumar

“…e13774 Background: Geriatric population forms a significant part of the total cancer patients in any given country and their expectations, their needs and…”
Get full text

Outcomes and adverse events of low-dose nivolumab in platinum refractory head and neck cancers by Kumar, Hemanth, Choudhary, Jatin, Ravikrishna, Madala, Menon, Nandini Sharrel, Patil, Vijay Maruti, Noronha, Vanita, Prabhash, Kumar, Joshi, Amit

“…6048 Background: Nivolumab is one of the recommended regimens for platinum refractory and second line treatment in head and neck cancers as per NCCN…”
Get full text

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation by Patil, Vijay Maruti, Noronha, Vanita, Menon, Nandini, Singh, Ajay, Ghosh-Laskar, Sarbani, Budrukkar, Ashwini, Bhattacharjee, Atanu, Swain, Monali, Mathrudev, Vijayalakshmi, Nawale, Kavita, Balaji, Arun, Peelay, Zoya, Alone, Mitali, Pathak, Shruti, Mahajan, Abhishek, Kumar, Suman, Purandare, Nilendu, Agarwal, Archi, Puranik, Ameya, Pendse, Shantanu, Reddy Yallala, Monica, Sahu, Harsh, Kapu, Venkatesh, Dey, Sayak, Choudhary, Jatin, Krishna, Madala Ravi, Shetty, Alok, Karuvandan, Naveen, Ravind, Rahul, Rai, Rahul, Jobanputra, Kunal, Chaturvedi, Pankaj, Pai, Prathamesh S, Chaukar, Devendra, Nair, Sudhir, Thiagarajan, Shivakumar, Prabhash, Kumar

“…There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell…”
Get full text

Nivolumab in platinum-refractory head-and-neck cancers: A retrospective observational audit from a tertiary cancer center by Patil, Vijay M., Muthuluri, Hemanth, Choudhary, Jatin, Parekh, Deevyashali, Abraham, George, Noronha, Vanita, Menon, Nandini, Dhumal, Sachin, Prabhash, Kumar

“…ABSTRACT Background: Nivolumab and pembrolizumab are approved treatment options for platinum-refractory head-and-neck squamous cell cancer (HNSCC) based on the…”
Get full text